文献速递细菌感染、耐药与抗菌药物

新型FtsZ抑制剂DS01750413对金黄色葡萄球菌具强效活性

Novel FtsZ inhibitor with potent activity against Staphylococcus aureus.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究评估了PC190723衍生物DS01750413(一种新型FtsZ抑制剂)对革兰阳性病原菌的体外活性,并在MRSA小鼠全身感染模型中验证体内疗效。结果显示DS01750413对MRSA临床分离株MIC为0.5-1 mg/L,呈浓度依赖性杀菌,并在小鼠菌血症模型中延长生存、降低肝脾肺肾细菌负荷。

要点

  • DS01750413对MRSA临床分离株MIC范围0.5-1 mg/L
  • 体外呈浓度依赖性杀菌活性
  • MRSA小鼠菌血症模型中延长生存并降低器官细菌负荷

核心结论

  • DS01750413对MRSA显示令人鼓舞的体外和体内活性,作为新型化学类别有望通过独特新靶点机制应对耐药问题。

研究设计与样本

  • 体外评估DS01750413与标准治疗抗生素对革兰阳性病原菌临床分离株的活性,并在MRSA所致小鼠全身感染模型中评估体内疗效。

主要发现

  • DS01750413对MRSA临床分离株MIC范围为0.5-1 mg/L,并显示浓度依赖性杀菌。
  • 在MRSA小鼠菌血症感染模型中,DS01750413治疗较安慰剂延长动物生存,并显著降低肝、脾、肺和肾的细菌负荷。

关键数值与推荐

  • DS01750413对MRSA临床分离株MIC范围为0.5-1 mg/L。

临床怎么用

  • 该结果支持DS01750413作为新型FtsZ抑制剂候选药物进一步开发,用于MRSA感染的潜在治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: FtsZ is an essential bacterial protein and an unexplored target for the development of antibacterial drugs. The development of a novel inhibitor targeting FtsZ offers a potential opportunity to combat drug resistance. DS01750413, a new derivative of PC190723, is a novel FtsZ inhibitor with improved in vitro and in vivo activity. The objective of this study was to investigate the efficacy of DS01750413 against Staphylococcus spp., including MRSA, in in vitro and in vivo models. METHODS: In vitro activities of DS01750413 and standard-of-care antibiotics were evaluated against clinical isolates of Gram-positive pathogens. The in vivo efficacy was evaluated in a murine systemic infection model caused by MRSA. RESULTS: DS01750413 showed potent in vitro activity against MRSA clinical isolates with MIC ranges of 0.5-1 mg/L and also demonstrated concentration-dependent bactericidal killing. In the murine bacteraemia infection model of MRSA, treatment with DS01750413 resulted in prolonged survival of animals compared with placebo-treated animals and exhibited a significant reduction in the bacterial load in liver, spleen, lungs and kidneys. CONCLUSIONS: DS01750413 showed encouraging in vitro and in vivo activity against MRSA. As a novel chemical class, DS01750413 has the potential to become clinically viable antibiotics to address the drug resistance problem by its unique novel targeting mechanism of action.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kumar M, Mathur T, Barman TK, et al. Novel FtsZ inhibitor with potent activity against Staphylococcus aureus. J Antimicrob Chemother. 2021. PMID: 34383913. doi:10.1093/jac/dkab270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。